Catabasis has shared its February 2020 update:
“February is all about the heart and that’s a big focus for us, too! Because the cardiac function is so vital to those affected by Duchenne, we’re passionate to learn more about the heart and edasalonexent in our Phase 3 PolarisDMD trial. In young boys affected by Duchenne, tachycardia (which is an elevated resting heart rate) is an early manifestation of cardiac disease. In our Phase 2 MoveDMD trial and open-label extension, we saw initial results suggesting that heart rate significantly decreased from baseline in boys receiving edasalonexent to approximately the average rate for unaffected boys.”
Catabasis is a community of experts from multiple disciplines who have come together with the common goal of bringing hope and life-changing therapies to patients and their families.
In 2008, they recognized that traditional approaches to drug discovery and development may not address the multiple underlying defects causing a disease, and founded Catabasis Pharmaceuticals. They set foot on a path forward leveraging a technology they now call their SMART (Safely Metabolized And Rationally Targeted) Linker drug discovery platform. With this platform, they have engineered molecules that simultaneously modulate multiple biological targets within one or more related disease pathways – thus allowing bioactives to reach their targets more efficiently and to have greater efficacy.